Oracle to bring AI capabilities to patient portal for medical records

ORLANDO - Oracle (NYSE: ORCL), a prominent player in the software industry with a market capitalization of $678 billion, announced plans to integrate AI capabilities into its Health Patient Portal, allowing patients to receive plain-language explanations of their medical records and ask questions about their health information directly within the system. According to InvestingPro data, the company’s strong 9.7% revenue growth reflects its continued expansion in healthcare technology solutions.

The new features, planned for general availability in 2026, will enable patients to request explanations of complex medical terminology, lab results, and treatment options through conversational AI powered by OpenAI’s technology.

According to the company’s press release, patients will be able to use the AI-enabled portal to simplify medical jargon, prepare questions for doctor visits, draft messages to clinicians, and schedule follow-up care.

"Delivering ChatGPT-like conversational experiences in the Oracle Health Patient Portal - built on OpenAI frontier models and within Oracle’s secure safeguards - demonstrates how responsible AI can empower patients with more information about their health," said Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences.

Oracle emphasized that no personal medical data will be stored by OpenAI, and the system will not generate diagnoses, medication recommendations, or treatment suggestions. Instead, it will focus on explaining complex medical concepts to help patients better understand their health information.

The company stated that AI-generated text will be visually highlighted and include citations of information sources for transparency.

This development follows Oracle’s recent release of an AI-enabled electronic health record system for clinicians. The announcement was made at the Oracle Health and Life Sciences Summit in Orlando.

In other recent news, Oracle has reported impressive first-quarter results, showcasing accelerating top-line growth and record sales performance across key metrics such as remaining performance obligations (RPO), Cloud Revenue, and Oracle Cloud Infrastructure (OCI). The company’s RPO saw a significant increase, reaching $455 billion, driven by large artificial intelligence contracts. Wolfe Research highlighted this growth by raising its price target to $400, noting the extraordinary demand in cloud infrastructure due to AI. Similarly, Barclays increased its price target to $347, emphasizing the impact of AI contracts on Oracle’s financials. Mizuho also raised its price target to $350, citing the company’s remarkable 359% year-over-year growth in RPO. Guggenheim adjusted its price target to $375, reflecting confidence in Oracle’s future within the software sector. Despite these positive developments, Oppenheimer maintained a Perform rating, acknowledging the impressive results but expressing concerns about capital expenditures. These updates reflect Oracle’s ongoing strength and growth in the technology landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.